Key result
Eight weeks of ANG II AT(1) receptor blocker treatment restored cardiac structure and function in alpha(2A)/alpha(2C)ARKO mice with sympathetic hyperactivity-induced heart failure.
Why the study?
Does ANG II AT(1) receptor blocker treatment improve cardiac structure and function in a genetic mouse model of sympathetic hyperactivity-induced heart failure?
Does ANG II AT(1) receptor blocker treatment improve cardiac structure and function in a genetic mouse model of sympathetic hyperactivity-induced heart failure?
Cardiac renin-angiotensin system activation plays a major role in the structural and functional abnormalities of sympathetic hyperactivity-induced heart failure, which can be reversed by AT1 receptor blockade.
Sympathetic hyperactivity may drive cardiac RAS activation in this genetic HF model; leaves open relevance to human disease progression.
Sympathetic hyperactivity (SH) and renin angiotensin system (RAS) activation are commonly associated with heart failure (HF), even though the relative contribution of these factors to the cardiac derangement is less understood. The role of SH on RAS components and its consequences for the HF were investigated in mice lacking alpha(2A) and alpha(2C) adrenoceptor knockout (alpha(2A)/alpha(2C)ARKO) that present SH with evidence of HF by 7 mo of age. Cardiac and systemic RAS components and plasma norepinephrine (PN) levels were evaluated in male adult mice at 3 and 7 mo of age. In addition, cardiac morphometric analysis, collagen content, exercise tolerance, and hemodynamic assessments were made. At 3 mo, alpha(2A)/alpha(2C)ARKO mice showed no signs of HF, while displaying elevated PN, activation of local and systemic RAS components, and increased cardiomyocyte width (16%) compared with wild-type mice (WT). In contrast, at 7 mo, alpha(2A)/alpha(2C)ARKO mice presented clear signs of HF accompanied only by cardiac activation of angiotensinogen and ANG II levels and increased collagen content (twofold). Consistent with this local activation of RAS, 8 wk of ANG II AT(1) receptor blocker treatment restored cardiac structure and function comparable to the WT. Collectively, these data provide direct evidence that cardiac RAS activation plays a major role underlying the structural and functional abnormalities associated with a genetic SH-induced HF in mice.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2007) studied Sympathetic hyperactivity-induced heart failure. ANG II AT(1) receptor blocker vs. Wild-type mice was evaluated on Cardiac structure and function. Eight weeks of ANG II AT(1) receptor blocker treatment restored cardiac structure and function in alpha(2A)/alpha(2C)ARKO mice with sympathetic hyperactivity-induced heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: